NDA 020936 · Apotex
Paxil Cr
Paroxetine Hydrochloride · Oral
Last checked: Nov 21, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Feb 16, 1999
Approved uses
4
Original approval plus efficacy supplements
Registered trials
275
60 Phase 3, 11 recruiting
FAERS reports
58,759
35,558 serious, 3,728 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [See Warnings and Precautions ( 5.1 )] PAXIL CR is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Antidepressants increase the risk of suicidal thoughts and behavior in pediatric and young adult patients ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). PAXIL CR is not approved for use in pediatric patients. ( 5.1 , 8.4)
What it is approved for
From the label in effect Sep 30, 2026.
PAXIL CR is indicated for the treatment of: Major depressive disorder (MDD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Premenstrual dysphoric disorder (PMDD) in adults PAXIL CR is a selective serotonin reuptake inhibitor (SSRI) indicated for use in adults for the treatment of ( 1 ): Major depressive disorder (MDD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Premenstrual dysphoric disorder (PMDD) in adults
Mechanism: The mechanism of action of PAXIL CR in the treatment of major depressive disorder (MDD), panic disorder (PD), social anxiety disorder (SAD), and premenstrual dysphoric disorder (PMDD) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-HT).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 27, 2004 Supplement 13 · Efficacy LetterLabel
- Oct 16, 2003 Supplement 12 · Efficacy LetterLabelReview
- Aug 28, 2003 Supplement 11 · Efficacy ReviewLabelLetter
- Feb 16, 1999 Original approval · Type 3 - New Dosage Form ReviewLabelOther Important Information from FDA
3 products under this application
- PAXIL CR · PAROXETINE HYDROCHLORIDE EQ 37.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- PAXIL CR · PAROXETINE HYDROCHLORIDE EQ 12.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- PAXIL CR · PAROXETINE HYDROCHLORIDE EQ 25MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Paroxetine" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03538691 · 1,149 participants · Start Jul 13, 2018 · Primary completion Jul 8, 2022
Drug: Brexpiprazole; Antidepressant therapy · For: Major Depressive Disorder
Sites: Los Angeles, California
- Algorithm Guided Treatment Strategies for Major Depressive DisorderPivotal-lookingStatus unknown
Shanghai Mental Health CenterAcademic, hospital or other
NCT01764867 · 1,080 participants (planned) · Start Jun 2012 · Primary completion Oct 2014
Drug: Escitalopram; Mirtazapine and 11 more · For: Major Depressive Disorder
Sites: Shanghai, China
- Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01715805 · 1,022 participants · Start Nov 15, 2012 · Primary completion Jun 24, 2016
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Tucson, Arizona; Little Rock, Arkansas; Cerritos, California · 85 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug withdrawal syndrome5,827
- nausea4,557
- drug ineffective4,412
- dizziness4,300
- anxiety4,175
- fatigue3,832
- headache3,563
- depression3,388
- drug exposure during pregnancy3,124
- insomnia2,934
- weight increased2,597
- diarrhoea2,585
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6,691 |
| 2005 | 6,081 |
| 2006 | 4,742 |
| 2007 | 2,990 |
| 2008 | 2,730 |
| 2009 | 2,644 |
| 2010 | 3,016 |
| 2011 | 3,113 |
| 2012 | 2,882 |
| 2013 | 1,735 |
| 2014 | 1,759 |
| 2015 | 3,467 |
| 2016 | 3,112 |
| 2017 | 1,936 |
| 2018 | 1,702 |
| 2019 | 1,714 |
| 2020 | 1,495 |
| 2021 | 1,367 |
| 2022 | 1,291 |
| 2023 | 1,171 |
| 2024 | 1,207 |
| 2025 | 1,095 |
| 2026 | 812 |
Recalls
7 FDA enforcement reports for this application.
Sep 23, 2026 · Class II · Ongoing
Failed dissolution specifications.
Aug 13, 2026 · Class II · Ongoing
Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria
Mar 24, 2014 · Class II · Terminated
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Mar 24, 2014 · Class II · Terminated
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Mar 24, 2014 · Class II · Terminated
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Mar 24, 2014 · Class II · Terminated
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Mar 24, 2014 · Class II · Terminated
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Paxil Cr (Paroxetine HCl)
2024 spending
$2.1M
Beneficiaries
648
3,152 claims
Per beneficiary
$3,273
$9.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,682,330 |
| 2021 | $2,585,096 |
| 2022 | $2,517,004 |
| 2023 | $2,545,720 |
| 2024 | $2,121,114 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis.
Williams T, McCaul M, Schwarzer G, et al. · Acta Neuropsychiatr 2020 · Comparative Study, Network Meta-Analysis
- Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis.
Zhang D, Cheng Y, Wu K, et al. · BMC Urol 2019 · Meta-Analysis, Systematic Review
- A systematic review and meta-analysis of randomized controlled trials of "on-demand" use of tramadol vs "on-demand" use of paroxetine in the management of patients with premature ejaculation.
Tan H, Zhou Z, Cui Y, et al. · Int J Clin Pract 2021 · Meta-Analysis, Systematic Review
- Efficacy and tolerability of second-generation antidepressants in social anxiety disorder.
Hansen RA, Gaynes BN, Gartlehner G, et al. · Int Clin Psychopharmacol 2008 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis.
Wei D, Chen Y, Wu C, et al. · BJOG 2016 · Meta-Analysis, Systematic Review
Sponsor: Apotex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.